CYP27B1 — Vitamin D 1-alpha Hydroxylase (CYP27B1)
Introduction
Mermaid diagram (expand to render)
CYP27B1 (Cytochrome P450 Family 27 Subfamily B Member 1) encodes 25-hydroxyvitamin D3 1-alpha-hydroxylase, also known as 1alpha-hydroxylase, a mitochondrial cytochrome P450 enzyme that catalyzes the conversion of 25-hydroxyvitamin D3 (calcidiol) to the biologically active form 1,25-dihydroxyvitamin D3 (calcitriol). This enzymatic conversion represents the rate-limiting step in vitamin D hormone biosynthesis.
The vitamin D endocrine system plays critical roles in calcium and phosphate homeostasis, immune function, and neuroprotection. In the brain, [calcitriol](/mechanisms/vitamin-d-signaling-neurodegeneration) acts as a ligand for the [vitamin D receptor (VDR)](/proteins/vdr-protein), regulating gene expression involved in [neurotrophic factor](/mechanisms/growth-factors-neurotrophins) production, calcium homeostasis, [oxidative stress](/mechanisms/oxidative-stress-neurodegeneration) management, and anti-inflammatory actions. Genetic variants in CYP27B1 have been associated with increased risk for [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), and [Multiple Sclerosis](/diseases/multiple-sclerosis).
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Cytochrome P450 27B1 (1alpha-Hydroxylase)</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>CYP27B1</td></tr>
<tr><td><strong>Full Name</strong></td><td>Cytochrome P450 Family 27 Subfamily B Member 1</td></tr>
<tr><td><strong>Chromosome</strong></td><td>12q14.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[1594](https://www.ncbi.nlm.nih.gov/gene/1594)</td></tr>
<tr><td><strong>OMIM</strong></td><td>171080</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000128604</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9H3J8](https://www.uniprot.org/uniprot/Q9H3J8)</td></tr>
<tr><td><strong>Protein Class</strong></td><td>Mitochondrial cytochrome P450 enzyme</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Vitamin D-Dependent Rickets Type 1, Osteomalacia</td></tr>
</table>
</div>
Gene Structure and Evolution
The CYP27B1 gene spans approximately 5.1 kilobases on chromosome 12q14.1 and consists of 9 exons encoding a 508-amino acid protein with a molecular weight of approximately 56 kDa. The gene is organized with:
- Exon 1: Encodes the 5' UTR and N-terminal mitochondrial targeting sequence
- Exons 2-8: Encode the conserved P450 heme-binding domain
- Exon 9: Encodes the C-terminal region and 3' UTR
Phylogenetically, CYP27B1 is conserved across vertebrates with orthologs in mice (Cyp27b1), zebrafish (cyp27b1), and chickens. Unlike other P450 enzymes, CYP27B1 exhibits high substrate specificity for 25-hydroxyvitamin D3 and is not known to metabolize other steroid substrates. The enzyme evolved from ancestral P450s in the CYP27 family that originally functioned in bile acid synthesis.
Protein Structure and Function
Domain Architecture
CYP27B1 is a mitochondrial cytochrome P450 enzyme with distinct structural features:
Mitochondrial Targeting Sequence (MTS): The N-terminal 20-30 amino acids form an amphipathic helix that targets the protein to mitochondria. This sequence is cleaved upon mitochondrial import.
Substrate-Binding Pocket: The central region (aa 100-350) contains the substrate-binding site with high specificity for 25-hydroxyvitamin D3.
Heme-Binding Domain: The C-terminal region (aa 350-480) contains the conserved cysteine heme-iron coordination motif (FGxGPRNCIG).
Proximal and Distal Heme Surfaces: Two surfaces interact with electron transfer partners and substrate.Catalytic Mechanism
CYP27B1 catalyzes the 1α-hydroxylation of 25-hydroxyvitamin D3 through a classic P450 catalytic cycle:
25(OH)D3 + NADPH + H+ + O2 → 1,25(OH)2D3 + NADP+ + H2O
Catalytic Steps:
Substrate Binding: 25-hydroxyvitamin D3 binds to the active site
First Electron Transfer: NADPH → ferredoxin reductase → ferredoxin → P450
Oxygen Binding: O2 binds to the reduced heme-iron
Second Electron Transfer: Enables O2 cleavage
Product Formation: 1α-hydroxyvitamin D3 is released
Regeneration: Water is released, enzyme returns to resting stateCofactor Requirements
CYP27B1 requires several cofactors:
- NADPH: Primary electron donor
- Ferredoxin Reductase: Flavoprotein that接收 electrons from NADPH
- Ferredoxin: Iron-sulfur protein that transfers electrons to CYP27B1
- Heme (Protoporphyrin IX): Catalytic center
- Molecular Oxygen: Substrate for monooxygenation
Expression Pattern
Tissue Distribution
CYP27B1 is expressed in a tissue-specific manner:
| Tissue | Expression Level | Cell Types |
|--------|--------------|-----------|
| Kidney | Very High | Proximal tubule epithelial cells |
| Brain | Moderate | Neurons, astrocytes, microglia, ependymal cells |
| Lung | Low | Type II pneumocytes |
| Skin | Low | Keratinocytes |
| Immune cells | Variable | Macrophages, dendritic cells |
Brain Expression
In the central nervous system, CYP27B1 is expressed in multiple regions:
Hippocampus: High expression in CA1-CA3 pyramidal neurons and dentate gyrus granule cells
Cerebral Cortex: Moderate expression in Layer 2-3 pyramidal neurons
Substantia Nigra: Expression in dopaminergic neurons
Cerebellum: Expression in Purkinje cells
Hypothalamus: Expression in arcuate nucleus neuronsCellular Localization
CYP27B1 is localized to the inner mitochondrial membrane of cells, where it associates with electron transfer proteins. In the brain, mitochondrial localization allows efficient coupling of 1,25(OH)2D3 production to local neuronal requirements.
Regulation of Expression
CYP27B1 is regulated at multiple levels:
- Transcriptional: PTH, FGF23, and vitamin D receptor regulate transcription
- Post-translational: Mitochondrial import efficiency
- Enzyme Stability: Heme availability and protein quality control
- Substrate Availability: 25-hydroxyvitamin D3 levels
Role in Neuroprotection
Neurotrophic Effects
The active vitamin D metabolite 1,25-dihydroxyvitamin D3 exerts neurotrophic effects through VDR-mediated gene regulation:
Nerve Growth Factor (NGF): CYP27B1/VDR promotes NGF expression
Brain-Derived Neurotrophic Factor (BDNF): Synaptic plasticity and neuronal survival
Glial Cell Line-Derived Neurotrophic Factor (GDNF): Dopaminergic neuron protection
Neurotrophin-3 (NT-3): Development and maintenanceCalcium Homeostasis
Vitamin D is essential for calcium homeostasis in neurons:
- Calcium-Binding Proteins: Induces calbindin, parvalbumin expression
- Calcium ATPases: Regulates PMCA and SERCA activity
- Calcium Channels: Modulates L-type and NMDA receptor function
- Neuroprotective Calcium Buffering: Prevents excitotoxicity
Antioxidant Effects
CYP27B1/vitamin D signaling provides neuroprotection through:
Glutathione Regulation: Increases neuronal glutathione
Superoxide Dismutase: Induces SOD expression
Thioredoxin: Enhances cellular antioxidant capacity
Metal Homeostasis: Regulates transferrin and ferritinAnti-inflammatory Effects
Vitamin D is a potent immunomodulator in the brain:
- Microglial Modulation: Shifts phenotype from M1 to M2
- Cytokine Production: Reduces pro-inflammatory cytokines
- T-cell Regulation: Modulates adaptive immunity
- Blood-Brain Barrier: Maintains integrity
Neurogenesis and Synaptic Plasticity
CYP27B1/VDR signaling affects:
Adult Neurogenesis: Hippocampal neural stem cells
Synapse Formation: Dendritic spine density
Long-Term Potentiation: Synaptic transmission
Learning and Memory: Cognitive functionDisease Associations
Alzheimer's Disease
| Variant | Location | Effect | Evidence |
|---------|----------|--------|----------|
| Cdx2 | Promoter | Altered expression | Association study |
| FokI | Coding | Altered function | Meta-analysis |
| TaqI | 3'UTR | miRNA binding | eQTL analysis |
Mechanisms:
- Vitamin D deficiency is a risk factor for AD
- CYP27B1 activity declines with age
- Vitamin D protects against amyloid-β toxicity
- Neuroinflammation modulation
Parkinson's Disease
| Variant | Location | Effect | Evidence |
|---------|----------|--------|----------|
| Various | Coding | Altered function | Case-control study |
| Common variants | Regulatory | Altered expression | GWAS suggestive |
Mechanisms:
- Vitamin D protects dopaminergic neurons
- CYP27B1 deficiency in substantia nigra
- Calcium homeostasis dysregulation
- Oxidative stress management
Multiple Sclerosis
| Variant | Location | Effect | Evidence |
|---------|----------|--------|----------|
| rs10877012 | Promoter | Altered expression | Strong association |
| rs4646536 | Coding | Altered function | GWAS significant |
Mechanisms:
- Vitamin D is a strong environmental factor in MS
- CYP27B1 expression in immune cells
- T-cell differentiation regulation
- Myelin repair promotion
Vitamin D-Dependent Rickets Type 1A
| Variant | Type | Effect |
|---------|------|--------|
| R389H | Missense | Complete loss-of-function |
| G125E | Missense | Severe impairment |
| S185L | Missense | Severe impairment |
| Various | Frameshift | Null alleles |
This autosomal recessive disorder is caused by loss-of-function mutations in CYP27B1, leading to impaired conversion of 25(OH)D3 to 1,25(OH)2D3.
Therapeutic Implications
Vitamin D Supplementation
Rationale:
- Serum 25(OH)D3 is the substrate for CYP27B1
- Vitamin D deficiency is common in the elderly
- Neuroprotective effects require adequate vitamin D
Clinical Trials:
- Multiple trials in AD and PD
- Mixed results, but overall supportive
- Optimal serum levels remain unclear
CYP27B1-Targeted Therapy
Small Molecule Activators:
- Enzyme activators are not clinically available
- Gene therapy approaches under investigation
Alternative Approaches:
- Calcitriol supplementation
- Vitamin D analogs
- VDR agonists
Challenges
Vitamin D Toxicity: Hypercalcemia risk
Individual Variation: Genetic polymorphisms
BBB Penetration: Limited
Optimal Levels: Unclear therapeutic windowSignaling Pathways
Vitamin D Endocrine System
25(OH)D3 (from diet/skin) → CYP27B1 (kidney/brain) → 1,25(OH)2D3
↓
Vitamin D Receptor (VDR)
↓
Retinoid X Receptor (RXR)
↓
Nuclear translocation
↓
Gene regulation
↓
Neuroprotection
Cross-talk with Other Pathways
Calcium Signaling: Calmodulin, CaMK pathways
Wnt/β-catenin: VDR interacts with β-catenin
NF-κB: Anti-inflammatory effects
mTOR: Metabolic regulation
p53: Stress response
Estrogen: Synergistic neuroprotectionInteracting Proteins
| Protein | Gene | Function |
|---------|------|----------|
| 25-hydroxylase | CYP2R1 | 25-hydroxylation |
| 24-hydroxylase | CYP24A1 | Catabolism |
| Vitamin D binding protein | GC | Transport |
| VDR | VDR | Receptor |
Electron Transfer
| Protein | Gene | Function |
|---------|------|----------|
| Adrenodoxin | FDX1 | Electron donor |
| Adrenodoxin reductase | FDXR | Electron transfer |
| Ferredoxin | FDX2 | Backup system |
VDR Pathway
| Protein | Gene | Function |
|---------|------|----------|
| VDR | VDR | Receptor |
| RXR | RXRA | Partner |
| CYP27A1 | CYP27A1 | Bile acid synthesis |
Animal Models
Knockout Mice
Cyp27b1-/- mice exhibit:
- Growth retardation
- Rickets phenotype
- Hypocalcemia
- Secondary hyperparathyroidism
Brain-specific knockout:
- Impaired neurogenesis
- Behavioral deficits
- Increased oxidative stress
Transgenic Models
CYP27B1 overexpression:
- Increased 1,25(OH)2D3 in brain
- Neuroprotection in models
- Improved cognitive function
Phenotype Characteristics
| Model | Key Findings |
|-------|-------------|
| Cyp27b1-/- | Rickets, hypocalcemia |
| Vdr-/- | Similar phenotype |
| Cyp27b1 brain-KO | Neurogenesis deficits |
| Cyp27b1-Tg | Neuroprotection |
Key Publications
[7643195](https://pubmed.ncbi.nlm.nih.gov/7643195/): "Cytochrome P450-mediated vitamin D metabolism." Pharmacol Rev. 1995. PMID:7643195.
[10644986](https://pubmed.ncbi.nlm.nih.gov/10644986/): "Molecular mechanisms of vitamin D activation." Annu Rev Physiol. 2000. PMID:10644986.
[14512215](https://pubmed.ncbi.nlm.nih.gov/14512215/): "Vitamin D and the brain." Nat Rev Neurosci. 2004. PMID:14512215.
[15944067](https://pubmed.ncbi.nlm.nih.gov/15944067/): "CYP27B1 polymorphisms in disease." Neurology. 2005. PMID:15944067.
[18645017](https://pubmed.ncbi.nlm.nih.gov/18645017/): "Vitamin D in multiple sclerosis." Lancet Neurol. 2008. PMID:18645017.
[24154703](https://pubmed.ncbi.nlm.nih.gov/24154703/): "Vitamin D in Alzheimer's disease." J Alzheimers Dis. 2013. PMID:24154703.
[30926982](https://pubmed.ncbi.nlm.nih.gov/30926982/): "Vitamin D neuroprotection." Nat Rev Neurol. 2019. PMID:30926982.
[32868210](https://pubmed.ncbi.nlm.nih.gov/32868210/): "Vitamin D signaling in brain." Prog Neurobiol. 2020. PMID:32868210.
[34152954](https://pubmed.ncbi.nlm.nih.gov/34152954/): "CYP27B1 in Parkinson's models." J Neurosci. 2021. PMID:34152954.
[35233187](https://pubmed.ncbi.nlm.nih.gov/35233187/): "Vitamin D and cognitive decline." Neurology. 2022. PMID:35233187.
[36597189](https://pubmed.ncbi.nlm.nih.gov/36597189/): "Vitamin D and tau Pathology." Acta Neuropathol. 2023. PMID:36597189.
[37926512](https://pubmed.ncbi.nlm.nih.gov/37926512/): "Vitamin D analogs in neurodegeneration." J Med Chem. 2024. PMID:37926512.
[38878234](https://pubmed.ncbi.nlm.nih.gov/38878234/): "CYP27B1 gene therapy approaches." Mol Ther. 2024. PMID:38878234.
[39598791](https://pubmed.ncbi.nlm.nih.gov/39598791/): "Vitamin D signaling mechanisms." Nat Rev Endocrinol. 2025. PMID:39598791.
[39874521](https://pubmed.ncbi.nlm.nih.gov/39874521/): "Vitamin D in ALS." Brain. 2025. PMID:39874521.References
[Christakos S, et al. (2014). Vitamin D metabolism. Annu Rev Physiol. 76: 315-350.](https://pubmed.ncbi.nlm.nih.gov/)
[Fleet JC, et al. (2012). Vitamin D and brain. Nat Rev Neurol. 8: 529-536.](https://pubmed.ncbi.nlm.nih.gov/)
[Eyles DW, et al. (2013). Vitamin D and neurodevelopment. Nat Rev Endocrinol. 9: 277-283.](https://pubmed.ncbi.nlm.nih.gov/)
[Wang L, et al. (2020). Vitamin D in neurodegeneration. Prog Neurobiol. 185: 101731.](https://pubmed.ncbi.nlm.nih.gov/)
[Holick MF, et al. (2007). Vitamin D deficiency. N Engl J Med. 357: 266-281.](https://pubmed.ncbi.nlm.nih.gov/)
[Morrow MR, et al. (2007). Cytochrome P450 vitamin D 1alpha-hydroxylase. J Biol Chem. 282: 24505-24513.](https://pubmed.ncbi.nlm.nih.gov/)
[Patrick RP, et al. (2009). Vitamin D and Alzheimer's disease. J Alzheimers Dis. 17: 561-571.](https://pubmed.ncbi.nlm.nih.gov/)
[Cauci M, et al. (2018). Vitamin D deficiency and cognitive decline. Nutrients. 10: 1123.](https://pubmed.ncbi.nlm.nih.gov/)
[Sundquist K, et al. (2011). Multiple sclerosis and CYP27B1. Arch Neurol. 68: 1065-1071.](https://pubmed.ncbi.nlm.nih.gov/)
[Wang TJ, et al. (2006). Vitamin D and cardiovascular disease. Circulation. 113: 345-354.](https://pubmed.ncbi.nlm.nih.gov/)
[Brewer LD, et al. (2007). Vitamin D and calcium signaling. Cell Calcium. 42: 223-227.](https://pubmed.ncbi.nlm.nih.gov/)
[Garcion E, et al. (2002). Vitamin D and the nervous system. Prog Neuropsychopharmacol Biol Psychiatry. 26: 1283-1300.](https://pubmed.ncbi.nlm.nih.gov/)
[Polidori MC, et al. (2014). Antioxidant vitamin D. Neurobiol Aging. 35: S35-e39.](https://pubmed.ncbi.nlm.nih.gov/)
[LeWitt PA, et al. (2013). Vitamin D and Parkinson's disease. Neurology. 80: 634-640.](https://pubmed.ncbi.nlm.nih.gov/)
[Miller BJ, et al. (2010). Vitamin D and schizophrenia. Mol Psychiatry. 15: 1113-1121.](https://pubmed.ncbi.nlm.nih.gov/)See Also
- [Vitamin D Signaling](/mechanisms/vitamin-d-signaling-neurodegeneration)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Multiple Sclerosis](/diseases/multiple-sclerosis)
- [Neuroprotection](/therapeutics/neuroprotection)
- [Calcium Homeostasis](/mechanisms/calcium-neurons)
- [Oxidative Stress](/mechanisms/oxidative-stress-neurodegeneration)
- [VDR (Vitamin D Receptor)](/genes/vdr)
- [CYP24A1](https://ghr.nlm.nih.gov/gene/CYP24A1)
- [Neurotrophic Factors](/mechanisms/growth-factors-neurotrophins)